WEBULL

Insider Spends US$100k Buying More Shares In Aytu BioPharma

Simply Wall St · 06/14/2025 12:30

Whilst it may not be a huge deal, we thought it was good to see that the Aytu BioPharma, Inc. (NASDAQ:AYTU) CEO & Director, Joshua Disbrow, recently bought US$100k worth of stock, for US$1.50 per share. While that isn't the hugest buy, it actually boosted their shareholding by 77%, which is good to see.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

The Last 12 Months Of Insider Transactions At Aytu BioPharma

In fact, the recent purchase by Joshua Disbrow was the biggest purchase of Aytu BioPharma shares made by an insider individual in the last twelve months, according to our records. Even though the purchase was made at a significantly lower price than the recent price (US$1.95), we still think insider buying is a positive. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

In the last twelve months Aytu BioPharma insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

Check out our latest analysis for Aytu BioPharma

insider-trading-volume
NasdaqCM:AYTU Insider Trading Volume June 14th 2025

Aytu BioPharma is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership Of Aytu BioPharma

I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. From looking at our data, insiders own US$500k worth of Aytu BioPharma stock, about 2.9% of the company. I generally like to see higher levels of ownership.

So What Does This Data Suggest About Aytu BioPharma Insiders?

It's certainly positive to see the recent insider purchases. And the longer term insider transactions also give us confidence. However, we note that the company didn't make a profit over the last twelve months, which makes us cautious. We would certainly prefer see higher levels of insider ownership but analysis of the insider transactions suggests that Aytu BioPharma insiders are expecting a bright future. So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing. At Simply Wall St, we've found that Aytu BioPharma has 3 warning signs (2 are a bit concerning!) that deserve your attention before going any further with your analysis.

But note: Aytu BioPharma may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.